All future 2014 events

View All Summary Expand all
Seminar - Dual orexin receptor antagonism: preclinical versus clinical aspects   View Summary
25 November 2014


Professor Daniel Hoyer, University of Melbourne

Professor Hoyer's research career can be traced from his PhD in Pharmacology (1981), DSc (1986 Strasbourg), post-doctoral work (University of Pennsylvania, Medical School, Pharmacology), via Cardiovascular Research at Sandoz (Basel, 1983) to the CNS division (1989). At Novartis, Hoyer worked on both drug development and basic science projeects, e.g. genomics of depression and schizophrenia (MPRC, Baltimore; Scripps & GNF, La Jolla), peptide receptors and their chemistry (European Consortium). His recent interests were in Epilepsy, Sleep disorders, RNAi and epigenetics.

Professor Hoyer has published over 300 papers, and is/was member of British and German Pharmacological Societies, European College of Neuropsychopharmacology, Society for Neurosciences, served at the scientific council of Institut Pasteur and on the Council and a Director of the BPS. Professor Hoyer has served as editor of European Journal of Pharmacology, Neuropharmacology, Current Opinions in Pharmacology, Current Drugs, Drug Discovery Today, Journal of Receptors & Signal Transduction, Pharmacology & Therapy. He is currently a senior editor of Psychopharmacology, Naunyn Schmiedeberg's Archives of Pharmacology, Encyclopedia of Psychopharmacology, British Journal of Pharmacology. Prof. Hoyer chaired the somatostatin and 5-HT receptor subcommittees (NC IUPHAR) and was President of the European Neuropeptide Club and of the International Society for Serotonin Research.

Professor Hoyer was in the top 10 most cited researchers in Pharmacology, Novartis Leading Scientist (1998), Manfred Zimmerman Award (2003), Professor adjunct at the Molecular and Integrative Neurosciences Department, Scripps Research Institute, La Jolla (2004), Fellow of the British Pharmacological Society (2005); since November 2012, Professor, Chair and Head, Department of Pharmacology, School of Medicine, The University of Melbourne.

Hosted by the Woolcock Institute

Seminar - SOFX transcription factors from the developmental biology to drug discovery   View Summary
25 November 2014


Dr Mathias Francois, Lab Head, Institute for Molecular Biology, The University of Queensland


Classic genetic approaches have established that SOXF (-7, -17 and -18) transcription factors play a central role to promote arterio-venous specification and lymphangiogenesis during development. Genetic ablation of these transcription factors in adult also prevent aberrant angio- and lymphangiogenesis that occur during cancer metastasis, establishing a proof of concept that SOXF are potential molecular target. Here we report that SOX-F transcriptional activity can be disrupted pharmaceutically and halt blood vascular development in vivo. This finding is based on a pipeline of screening tools that range from homogenous in vitro assays to angiogenic zebrafish model system. Our discovery provides a basis for innovative pharmacological manipulation of SOX-F proteins function and challenge prevailing dogma that transcription factors are not suitable drug targets.

Dr. Mathias Francois' PhD focused on the role of nuclear receptors PPARs in the control of the inflammatory reaction during osteoarthritis. In 2005, Mat moved to the Koopman Laboratory at IMB Queensland to study the role of SOX transcription factor in the control of lymphatic vessel development. During his post doc, Mat discovered the role of SOX18 as a molecular switch at the origin of the lymphatic vasculature. Part of his work focuses on the initial step of endothelial cell specification and the molecular hierarchy that governs this differentiation program during embryogenesis.

Hosted by theCentenary Institute

Lecture: Cancer research - where to from here?   View Summary
26 November 2014


Professor Ian Frazer AC, Chief Executive Officer and Director of Research at the Translational Research Institute, Brisbane

Hosted by The University of Sydney Cancer Research Network

Symposium - Australian Society for Performing Arts Healthcare   View Summary
26 November 2014

The event will feature keynote speaker Victor Popov, a sports physiotherapist with
extensive experience in the treatment of musician and dancers' injuries.

Seminar - An energy balance approach to reducing obesity   View Summary
2 December 2014


Professor James Hill from the University of Colorado.

More information
Team-based learning (TBL) seminar and workshops   View Summary
11 December 2014 to 12 December 2014


Larry Michaelsen, Professor of Management, University of Central Missouri

More information
Seminar - Developing in vitro model systems for investigations of motor neurone disease   View Summary
12 December 2014


Jeremy Toma, Dalhousie University, Halifax, Canada


Motor neurone disease (MND) is a devastating neurodegenerative disorder whereby the cells that control muscles - the motor neurones - degenerate and die, resulting in paralysis and death. As there is no effectivetreatment or cure for MND, there is a great need for developingtherapeutics. The focus of my work has been to generate motor neurones from different cellular sources, including induced pluripotent stem cells and skin cells, and to assess the ability of these sources to generate functional motor neurones capable of being used for MND
therapeutics. The suitability of this approach for developing effective MND therapeutics will be discussed.